Categories: News

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157873. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

Staff

Recent Posts

Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE:…

1 hour ago

Don’t Let the Fear of Prep Stop You from Being Screened

Patients and experts highlight the importance of colorectal cancer screening and prevention CENTER VALLEY, Pa.,…

5 hours ago

Garrett and Rohde & Schwarz develop an integrated solution for high security screening applications

Garrett integrates its walk-through metal detector with the Rohde & Schwarz' R&S QPS201 security scanner. The…

5 hours ago

FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 2, 2025 /PRNewswire/…

5 hours ago

University Lab Partners Welcomes Groundbreaking MedTech Companies to the I-CREATE Accelerator Program

IRVINE, Calif., April 2, 2025 /PRNewswire/ -- University Lab Partners (ULP) proudly announces the selection…

5 hours ago

PrimeRx Pharmacy Ecosystem: Helping Independent Pharmacies Stay Ahead of the Curve and Accelerate Growth

UNIONDALE, N.Y., April 2, 2025 /PRNewswire/ -- PrimeRx, a trusted leader in pharmacy management solutions, is…

5 hours ago